Unique business model

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the Group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.

Strategy & goals

The strategic goal of the M1 Kliniken Group is to offer high quality medical services. Beauty products, beauty treatments and aesthetic surgeries are subject to high price sensitivity. The German Society for Consumer Research (GfK) has identified that the average market prices for breast surgery, liopsuction and wrinkle treatment are too expensive from the customer's point of view. The range of products and services offered by M1 Kliniken Group is therefore based on the price expectations of customers. By offering the highest quality at the best price, the demand for beauty treatments and aesthetic surgeries is increasing and new customer groups are being established.

Latest news

| Investor News

  • Group: sales +11.2% to EUR 167.7 million and EBIT +98.8% to EUR 14.5 million
  • Earnings per share increased from EUR 0.17 to EUR 0.53
  • Beauty segment: sales +30.6% and EBIT +24.3%
  • Profitable growth to be continued

As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG.

Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasing and sales, which he was previously responsible for together with Co-CEO Attila Strauss, will in future be managed by Attila Strauss alone.

In the first quarter of 2024, the M1 Group increased its consolidated sales by 9.6% from EUR 76.8 million to EUR 84.7 million. In comparison, operating earnings before interest and taxes (EBIT) increased at a disproportionately high rate. M1 improved Group EBIT by 70% from EUR 4.0 million to EUR 6.8 million. The Group EBIT margin increased accordingly from 5.3% to 8.1%.